• Inotek Pharmaceuticals

    Inotek Pharmaceuticals has initiated a phase 2 study of trabodenoson in combination with latanoprost to reduce IOP in patients with glaucoma or ocular hypertension. The company hopes trabodenoson can complement existing drugs by acting on the trabecular meshwork to provide improved IOP-lowering effect. 

    The randomized, double-masked, active-controlled, multi-center study compares trabodenoson plus latanoprost to timolol plus latanoprost in 120 patients. The three-month study will measure the additive or synergistic IOP-lowering effect of once- and twice-daily trabodenoson when combined latanoprost and will also evaluate the safety and tolerability of the combined treatment regimen. Top line data is expected in the fourth quarter of this year.

    “Trabodenoson has already been shown to significantly lower the IOP of non-human primates when added to all the classes of glaucoma drugs commonly used”, said Rudolf Baumgartner, chief medical officer of Inotek Pharmaceuticals. “These results support the complementarity of trabodenoson’s novel mechanism of action, which we believe is acting on the most important outflow path – the trabecular meshwork.”